2-oxindole compounds
Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having a formula selected from the group consisting of (Ia1), (Ia2), and (Ia3):
or a pharmaceutically acceptable salt thereof, wherein
Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R 3 ;
L 1 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,
L 2 is selected from the group consisting of a bond, C 1-6 alkylene, and C 1-6 heteroalkylene,
each R 1 is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, OH, CN, C 1-3 alkyl, C 1-3 haloalkyl, and C 1-3 alkoxy;
each R 3 is independently selected from the group consisting of halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-6 cycloalkyl, and C 2-6 alkenyl; and
the subscript n is an integer of from 0 to 3.
2. The pharmaceutical composition claim 1 , wherein Ar is selected from phenyl, pyridyl, and quinolinyl, each of which is optionally substituted with from one to two R 3 .
3. The pharmaceutical composition claim 1 , wherein L 1 is selected from the group consisting of a bond, —CH 2 — and —CH(CH 3 )—.
4. The pharmaceutical composition claim 1 , wherein L 2 is selected from the group consisting of a bond, —O—CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 —, and —CH 2 CH 2 CH 2 —.
5. The pharmaceutical composition of claim 1 , wherein n is 1 or 2.
6. The pharmaceutical composition claim 1 , wherein Ar is selected from the group consisting of 1,3-phenylene and 1,4-phenylene, each of which is optionally substituted with from one to two R 3 .
7. The pharmaceutical composition claim 1 , wherein R 1 is selected from the group consisting of halogen, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, C 3-5 cycloalkyl, and C 2-3 alkenyl.
8. The pharmaceutical composition claim 1 , wherein R 1 is selected from the group consisting of chloro, methyl, cyano, ethyl, cyclopropyl, trifluoromethyl and trifluoromethoxy.
9. The pharmaceutical composition claim 1 , wherein the compound has a formula selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, wherein said compound is at least 90% free of other isomers.
10. The pharmaceutical composition of claim 1 , wherein R 1 is chloro.
11. The pharmaceutical composition of claim 1 , wherein the compound has the formula
or a pharmaceutically acceptable salt thereof.
12. The pharmaceutical composition of claim 1 , wherein the compound has the formula
or a pharmaceutically acceptable salt thereof.
13. The pharmaceutical composition of claim 1 , wherein the compound has the formula
or a pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition of claim 1 , wherein the compound has the formula
or a pharmaceutically acceptable salt thereof.